Healthcare Jan 17, 2022 10:13 AM (GMT+8) · EqualOcean
Yiouda health on January 17, today, AI + RNA start-up Revir therapeutics (xigravel technology, hereinafter referred to as Revir) announced that after the angel round financing of Wuyuan capital and CDH VGC in May 2021, it completed the pre-A financing support invested by Shunwei capital, Yunjiu capital and Tiantu, and was over invested by the old shareholders Wuyuan capital and CDH VGC, with a total financing amount of tens of millions of dollars. It is reported that this round of funds will be used to continue to promote Voyager under Revir ™ Evaluation and verification of AI technology platform. By combining machine learning with advanced RNA biology R & D technology, Revir will further accelerate the screening and development of its candidate compounds and lay a foundation for extensive clinical application layout. Founded in May 2021, Revir is committed to driving the drug research and development of targeted RNA with artificial intelligence algorithms and gene technology, so as to solve the long-term unmet clinical needs such as tumors, infections and rare diseases. Revir and its core technical team focus on the calculation of RNA spatial structure, analyze the RNA structure through algorithm and large-scale sequencing, and develop the "pocket" in the RNA structure of small molecule drugs, that is, its active site, so as to block the mechanisms such as shear translation, achieve the purpose of treating diseases, and achieve a breakthrough in the "non drug" target at the protein level.